In-Vitro Diagnostics Enzymes Market

Market Overview:

The global in-vitro diagnostics enzymes market size reached US$ 2.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7.7% during 2024-2032.

In-vitro diagnostics are tests that are done on certain samples, including blood and tissue derived from the human body. They involve the use of assays and reagents to diagnose the medical condition in patients. They assist in providing necessary information pertaining to the diagnosis, screening, and monitoring of the ailment for the treatment and prevention of the same. Enzymes are widely employed in these diagnostic solutions for the detection of an extensive range of illnesses due to their excellent biocatalytic properties. Various enzymes, such as gelatinase-B, alanine transaminase, creatine kinase, acid phosphatase, aspartate transaminase and lactate dehydrogenase, are used as preferred biomarkers for the diagnosis of numerous ailments, including renal disease, cancer and rheumatoid arthritis.

The global market is primarily driven by the increasing demand for effective infectious disease diagnosis. This has led to the continual developments in the polymerase chain reaction (PCR) and its widespread applicability across the healthcare sector. PCR enables the easy detection of various organisms with improved precision and sensitivity, thereby providing an impetus to the market growth. Moreover, the development of enzyme biosensors has resulted in a considerable rise in enzyme utility for clinical diagnosis of certain medical conditions, such as tuberculosis, atypical pneumonia, streptococcal pharyngitis and ulcerative urogenital infections. This, in turn, is creating a positive outlook for the market. Apart from this, the rising number of cancer cases across the globe has led to the increasing demand for efficient diagnostic solutions that require the utilization of enzymes for histopathology of biopsy samples. Some of the other factors contributing to the market growth include continual improvements in the healthcare infrastructure and the rising investments in research and development (R&D) activities.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global in-vitro diagnostics enzymes market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on enzyme type, disease type, technology type and end use.

Breakup by Enzyme Type:

• Proteases
• Polymerase and Transcriptase
• Ribonuclease
• Others
   

Breakup by Disease Type:

• Infectious Disease
• Diabetes
• Oncology
• Cardiology
• Nephrology
• Autoimmune Diseases
• Others
   

Breakup by Technology Type:

• Histology Assays
• Molecular Diagnostics
• Clinical Chemistry
   

Breakup by End Use:

• Pharma and Biotech Companies
• Hospital and Diagnostic Labs
• Contract Research Organizations (CROs)
• Others
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Advanced Enzymes Technologies Ltd., Affymetrix (Thermo Fisher Scientific), Amano Enzyme Inc., American Laboratories Inc., Amicogen Inc., BBI Solutions, Biocatalysts Limited (Brain AG), Codexis Inc., Dyadic International Inc., F. Hoffmann-La Roche AG and Merck KGaA.

Report Coverage: